Health Economics and Outcomes Research (HEOR)

Evidence-based decision making in healthcare

A robust, comprehensive evidence base is crucial in demonstrating the effectiveness and value of healthcare technologies to payers and other stakeholders.

Evidence-based decision-making fuels the life sciences sector and is key to each and every step of the product lifecycle, from go/no go decisions on clinical trials to the development of global market access strategies.

All stakeholders, including Health Technology Assessment (HTA) agencies, national payers, healthcare providers and local prescribers, evaluate a technology’s clinical, economic and health outcomes evidence base.

Health Economics and Outcomes Research (HEOR) teams are responsible for identifying, synthesising and presenting evidence in a way that clearly demonstrates the value a product offers for patients and for healthcare systems.

Work with our HEOR consultants

HEOR as a discipline brings together two key areas of specialism: health economics and outcomes research.

Our in-house team of HEOR consultants, health economists, evidence review analysts and statisticians work together to generate the clinical and economic evidence required for internal and external decision making.

As a leading HEOR consultancy, we combine rigorous academic protocols with a deep understanding of the commercial requirements and financial challenges of global healthcare markets.

This enables us to generate an evidence base and present data in a way that resonates with reimbursement agencies and local payers.

We can help you develop a roadmap of activities that will build a strong evidence base to support your product’s value proposition.

To discuss your HEOR needs with our HEOR specialist consultants, get in touch using the form below.

Our HEOR services

Evidence Synthesis

Evidence mapping and scoping reviews for strategic insight
Systematic literature reviews – the gold standard for HTA and published evidence
Living reviews that maintain an up-to-date evidence base
Trial data and real-world evidence
Risk of bias assessments
Market landscape reviews
Rapid and pragmatic approaches
Umbrella reviews

Meta-analysis feasibility and network meta-analysis
Bespoke statistical analyses
Critiques of reviews and meta-analyses
Publication strategies
PROSPERO submission

Learn more

Evidence mapping and scoping reviews for strategic insight
Systematic literature reviews – the gold standard for HTA and published evidence
Living reviews that maintain an up-to-date evidence base
Trial data and real-world evidence
Risk of bias assessments
Market landscape reviews
Rapid and pragmatic approaches
Umbrella reviews
Meta-analysis feasibility and network meta-analysis
Bespoke statistical analyses
Critiques of reviews and meta-analyses
Publication strategies
PROSPERO submission

Health Economics

Development and critique of health economics strategy
Early economic modelling
Global cost-effectiveness and budget impact models
Country adaptations of global models
Modelling support for HTA submissions
Technical documentation and manuscript writing
Models for use with local payers

Learn more

HEOR and Evidence Synthesis

Download our Health Economics & Outcome Research

Discover how our experts in health economics, systematic literature review and network meta-analysis can help you build a strong evidence base. Download brochure.

Download Brochure

“

“The support from the Mtech Access team was outstanding. The Mtech Access health economists inputted into the systematic reviews to make sure everything ran smoothly for the models. I have come to realise that there are many benefits that come from having the Systematic Review, Network Meta-Analysis and Health Economics models done by the same agency.”
Global Health Economics DirectorPharma Company

“

“Facing pressing resubmission deadlines, we reached out to Mtech Access to update our Systematic Literature Review and Data Analysis. I was very glad we did. We received the optimal outcome given the timelines – overall a very successful project!”
Global HEOR DirectorPharma Company

“

“We realised how important it was when developing a health economic model to have local affiliates involved and engaged from the start, as they are going to be the end users. Working in this way means that the models are mostly adapted to local market needs already at the beginning, which means affiliates will save time and money in the long run as the model is more fit for purpose.”
Global Health Economics Director Pharma Company

“

“The proposal, cost and timelines were all great and I was pleased with the project management. I previously worked at several agencies, so I always think about how much I would have charged for similar services, and your costs were spot on.”
Communication SpecialistMedical Device Company

“

“The health economic modelling for our HTA submission was difficult and complex, but the Mtech Access Health Economist came up with lots of ideas, working with our team to overcome these challenges; it was just like having another colleague around the table.”
Head of Market Access, UK & IrelandPharma Company

“

“Honestly, the best agency I have ever worked with. It felt like we were working with a partner and not an agency! The Mtech Access Evidence Consultant we worked with was the driving force for this project’s success. She set up the scope and plan, nailed the systematic review protocol and delivered great quality work requiring very few changes. The manuscript is now a central piece of evidence in our work with external stakeholders; it is a high-quality piece of work that is proving vital to our conversations.”
Global Medical DirectorTop 20 Pharma Company

Featured Case Studies

Delivering on global market access strategy, evidence generation and communication objectives

View Case Study
Evaluating existing research and identifying evidence gaps to inform future research priorities

View Case Study
Synthesising gold standard clinical and economic evidence for each step of the reimbursement and market access journey

View Case Study
Building a budget impact model for AMCP submission in the US

View Case Study

Key steps in the HEOR journey

HEOR strategy and evidence generation planning

Before commissioning a systematic review or cost-effectiveness model, it is important to take a broad look across the market landscape and consider your wider commercial goals.

To ensure you generate the right evidence, you may need to consider:

How will your evidence base be used?
Who are the key stakeholders and what will they be looking to understand?
Will your evidence base be used for internal or external decision making?
Will different markets/reimbursement bodies/payers have different requirements?
Do your clinical trial data fully meet your reimbursement needs or is further data collection required?
How does your evidence sit within the existing published literature?

Our HEOR experts draw on extensive experience to recommend an evidence strategy to meet your needs.

Synthesising HEOR data

HEOR data are brought together from many sources.

The product’s clinical trial data are analysed alongside systematic reviews of published data for competitor products.

Real-world data and real-world evidence are increasingly used to supplement data collected in the clinical trial setting.

These data are combined with pricing data in Health Economic models that estimate the value of the product against its competitors.

HEOR methodologies

How do we synthesise HEOR data to develop an evidence base?

We employ a wide range of HEOR methodologies to develop an evidence base that supports healthcare decision making.

Our evidence analysts offer a range of options for literature reviews, from gold-standard systematic literature reviews (required for most HTA submissions) to rapid reviews and scoping reviews.

We also have in-house experts in statistical analysis, including network meta-analysis.

Our health economists can develop all health economic model types, including:

Decision trees, Markov and semi-Markov models, partitioned survival models, discrete event simulations, and regression-based models
Cost-effectiveness, cost-utility, cost-minimisation, cost-benefit, cost-consequence and budget impact models

Learn more about evidence generation

Learn more about health economic modelling

Medical writing for HEOR

HEOR outputs are often detailed and complex. In order for HEOR data and conclusions to play a productive role in healthcare decision-making, the evidence must be presented in a way that is scientifically rigorous yet accessible, clear and compelling. This is the expertise of medical writing.

Our in-house team of technical writers and market access consultants work closely with our evidence analysts and health economists to present your data in a way that will resonate with payers, reimbursement bodies and other decision makers.

We can prepare your evidence base as:

An internal global value dossier
A reimbursement dossier for local teams to adapt for different HTA bodies
HTA submission dossiers, including for NICE and SMC
Publications in journals or as conference abstracts and posters

Learn more about HTA support

HEOR news and insights

Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics

We bring together specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024-25. Jump in, as our experts give their hot-take on each trend, sharing their perspectives on what’s happening in these areas…

Navigating US payer evidence needs to optimise market access

How can you optimise your chances of preferential access in the US with the right evidence? Join Clare Foy (Director – Global Market Access, Mtech Access) as she interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges…